EI
ELVN icon

EAM Investors’s Enliven Therapeutics ELVN Stock Holding History

EAM Investors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57M Sell
70,432
-12,362
-15% -$525K 0.32% 145
2026
Q1 		$3.25M Buy
+82,794
New +$2.29M 0.37% 131

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

EAM Investors's ELVN Position: Q2 2026 in Review

EAM Investors reduced its Enliven Therapeutics (ELVN) stake by 15% in Q2 2026, selling an estimated $525K and leaving 70,432 shares worth $3.57M. The position accounts for 0.32% of the portfolio, ranked #145.

EAM Investors first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • EAM Investors held 70,432 shares of Enliven Therapeutics worth $3.57M as of Q2 2026.
  • EAM Investors sold 12,362 Enliven Therapeutics shares in Q2 2026, an estimated $525K.
  • Enliven Therapeutics made up 0.32% of EAM Investors's portfolio in Q2 2026, its #145 holding.
  • EAM Investors first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.